Page 34 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine Chinese Expert Consensus for LACC

advanced cervical cancer. Am J Clin Oncol. 2022;45(7): with chemoradiotherapy for locally advanced cervical
286-293. cancer (CALLA): A randomised, double-blind, phase 3 trial.
Lancet Oncol. 2023;24(12):1334-1348.
doi: 10.1097/COC.0000000000000926
doi: 10.1016/S1470-2045(23)00479-5
13. Wang J, Jiang P, Wei L, et al. 759P Nimotuzumab combined
with concurrent chemo-radiotherapy in patients with locally 23. Duska LR, Scalici JM, Temkin SM, et al. Results of an
advanced cervical squamous cell carcinoma: A randomized, early safety analysis of a study of the combination of
controlled, open-label, multicenter study. Ann Oncol. pembrolizumab and pelvic chemoradiation in locally
2023;34:S518-S519. advanced cervical cancer. Cancer. 2020;126(22):4948-4956.
14. Qu A, Wang J, Zhuo Y, et al. 760P Efficacy and safety of doi: 10.1002/cncr.33136
nimotuzumab plus radiotherapy for elderly patients with 24. Lorusso D, Xiang Y, Hasegawa K, et al. LBA38
locally advanced cervical squamous cell carcinoma. Ann Pembrolizumab plus chemoradiotherapy for high-risk
Oncol. 2023;34:S519.
locally advanced cervical cancer: A randomized, double-
15. Yuan Y, Chen J, Fang M, et al. Nimotuzumab combined with blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18
chemoradiotherapy for the treatment of cervical cancer: study. Ann Oncol. 2023;34:S1279-S1280.
A meta-analysis of randomized controlled trials. Front 25. McCormack M, Rincón DG, Eminowicz G, et al. LBA8
Oncol. 2022;12:994726.
A randomised phase III trial of induction chemotherapy
doi: 10.3389/fonc.2022.994726 followed by chemoradiation compared with chemoradiation
alone in locally advanced cervical cancer: The GCIG
16. Rodrigues M, Vanoni G, Loap P, et al. Nivolumab plus INTERLACE trial. Ann Oncol. 2023;34:S1276.
chemoradiotherapy in locally-advanced cervical cancer: The
NICOL phase 1 trial. Nat Commun. 2023;14(1):3698. 26. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for
first-line treatment of PD-L1-selected patients with NSCLC.
doi: 10.1038/s41467-023-39383-8
N Engl J Med. 2020;383(14):1328-1339.
17. Xiao Y, Cheng H, Wang L, Yang L, Yu X. 562P Camrelizumab doi: 10.1056/NEJMoa1917346
plus concurrent chemoradiotherapy for locally advanced
cervical cancer: Preliminary results of a single-arm, open- 27. Emens LA, Adams S, Barrios CH, et al. First-line
label, phase II trial. Ann Oncol. 2022;33:S805. atezolizumab plus nab-paclitaxel for unresectable, locally
advanced, or metastatic triple-negative breast cancer:
18. Patel TH, Brewer JR, Fan J, et al. FDA approval summary:
Tremelimumab in combination with durvalumab for the IMpassion130 final overall survival analysis. Ann Oncol.
2021;32(8):983-993.
treatment of patients with unresectable hepatocellular
carcinoma. Clin Cancer Res. 2024;30(2):269-273. doi: 10.1016/j.annonc.2021.05.355
doi: 10.1158/1078-0432.CCR-23-2124 28. Powles T, Duran I, van der Heijden MS, et al. Atezolizumab
versus chemotherapy in patients with platinum-treated
19. Powles T, van der Heijden MS, Castellano D, et al.
Durvalumab alone and durvalumab plus tremelimumab locally advanced or metastatic urothelial carcinoma
(IMvigor211): A multicentre, open-label, phase 3
versus chemotherapy in previously untreated patients with randomised controlled trial. Lancet. 2018;391(10122):
unresectable, locally advanced or metastatic urothelial 748-757.
carcinoma (DANUBE): A randomised, open-label,
multicentre, phase 3 trial. Lancet Oncol. 2020;21(12): doi: 10.1016/S0140-6736(17)33297-X
1574-1588. 29. Mayadev J, Zamarin D, Deng W, et al. Safety and
doi: 10.1016/S1470-2045(20)30541-6 immunogenicity of anti PD-L1 (Atezolizumab) given as
an immune primer or concurrently with extended field
20. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus chemoradiotherapy for node positive locally advanced
gemcitabine and cisplatin in advanced biliary tract cancer. cervical cancer: An NRG oncology trial (024). Gynecol
NEJM Evid. 2022;1(8).
Oncol. 2022;166:S18-S19.
doi: 10.1056/EVIDoa2200015
doi: 10.1016/S0090-8258(22)01242-2
21. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus 30. Ray-Coquard IL, Kaminsky-Forrett MC, Ohkuma R,
platinum-etoposide versus platinum-etoposide in first- et al. In situ immune impact of nivolumab + ipilimumab
line treatment of extensive-stage small-cell lung cancer combination before standard chemoradiation therapy
(CASPIAN): A randomised, controlled, open-label, phase 3 (RTCT) for FIGO IB3-IVA in patients (pts) with cervical
trial. Lancet. 2019;394(10212):1929-1939.
squamous carcinoma: COLIBRI trial, a GINECO study.
doi: 10.1016/S0140-6736(19)32222-6 J Clin Oncol. 2023;41:5501.
22. Monk BJ, Toita T, Wu X, et al. Durvalumab versus placebo doi: 10.1200/JCO.2023.41.16_suppl.5501

Volume 3 Issue 1 (2025) 26 doi: 10.36922/arnm.4032